WHO ICTRP trial
Anti-depressants for depression in Huntington's disease
ISRCTN87426672 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN87426672 |
|---|---|
| Public title | Anti-depressants for depression in Huntington's disease |
| Scientific title | Developing EVIdence for AntidepreSsant ChoicE to Treat Depression in Huntington’s Disease |
| Primary sponsor | Cardiff University |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase IV |
| Countries | England;United Kingdom;Wales |
| Conditions | Antidepressant treatment for depression in individuals with a confirmed genetic diagnosis of Huntington's Disease. Mental and Behavioural Disorders |
| Interventions | Randomisation will take place online through a bespoke system built for the trial to maintain the blind. Participants will be randomised to receive either 50mg of sertraline or Placebo daily for 6 months. Participants will take the IMP… |
| Registration date | Feb 10, 2025 |
| Target size | 40 |
| Secondary IDs | Nil known;Nil known;02-TC-24-024 |
| Registry page | isrctn.com |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: